Vertex Kicks Off Telaprevir Pivotal Trial Next Month
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbreviated 24-week HCV therapy regimen with telaprevir could also prove itself in vast population of treatment non-responders, company says.